ACE2 and neoplasm: Our in vivo experiments confirmed that the mRBD3dopa-BTZ conjugate showed lower systemic toxicity (as evidenced by ALP levels) and improved selectivity, achieving ∼1.7-fold higher tumor accumulation while reducing distribution to non-target ACE2-expressing organs (liver, kidney, and heart) (Fig. 6, A and C and Data S7).